XML 27 R14.htm IDEA: XBRL DOCUMENT v3.8.0.1
Segment Reporting
 3 Months Ended
Mar. 31, 2018
Segment Reporting [Abstract]  
Segment Reporting
Segment Reporting. We report our operations in two operating segments: cardiovascular and endoscopy. Our cardiovascular segment consists of cardiology and radiology medical device products which assist in diagnosing and treating coronary artery disease, peripheral vascular disease and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management ("CRM"), electrophysiology ("EP"), critical care, and interventional oncology and spine devices. Our endoscopy segment consists of gastroenterology and pulmonology medical device products which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. We evaluate the performance of our operating segments based on operating income. 

Financial information relating to our reportable operating segments and reconciliations to the consolidated totals for the three-month periods ended March 31, 2018 and 2017, are as follows (in thousands):

 
Three Months Ended March 31,
 
2018
 
2017
Net Sales (1)
 

 
 

Cardiovascular
$
195,855

 
$
164,754

Endoscopy
7,180

 
6,315

Total net sales
203,035

 
171,069

 
 
 
 
Operating Income (1)
 
 
 
Cardiovascular
6,397

 
3,981

Endoscopy
2,384

 
1,628

Total operating income
8,781

 
5,609


(1) Sales and operating income have been adjusted from prior disclosure to reflect changes in product classifications between our operating segments, which were made to be consistent with updates in the management of our product portfolios in 2018.